Thorell Marella 4

What Happened
Thorell Marella, EVP and Chief Financial Officer of Seres Therapeutics (MCRB), was granted a 22,500-share derivative award (reported as A) on 2026-03-04. The award is reported at $0.00 (no cash exchanged at grant) and is a stock option-type award subject to vesting rather than an immediate purchase or sale.

Key Details

• Transaction date: 2026-03-04; Form 4 filed: 2026-03-06 (timely filing).
• Transaction type/code: A (grant/award); reported as a derivative instrument at $0.00.
• Shares involved: 22,500-share award. Reported total value: $0 (no cash paid).
• Vesting (footnote): 25% vests on March 2, 2027; remaining 75% vests in 12 equal quarterly installments thereafter (effectively a four‑year schedule).
• Shares owned after transaction: Not disclosed in the provided filing summary.
• Remarks: Marella is EVP and Chief Financial Officer.

Context
This is a compensation award (option-like derivative) subject to a multi-year vesting schedule—common for executive incentives. It does not represent an immediate purchase or sale of shares and does not by itself indicate insider buying or selling intent.